Gilead Sciences New Data from Trodelvy® Study
Gilead Sciences (GILD) has recently announced new data from the Phase 3 ASCENT study evaluating Trodelvy® in patients with relapsed or refractory metastatic triple-negative breast cancer (TNBC) who received two or more prior systemic therapies, at least one of them for metastatic disease.

Trodelvy has shown to improve progression-free survival (PFS . . .